Premium
Therapeutic cytapheresis in chronic lymphocytic leukemia
Author(s) -
Marti G. E.,
Folks T.,
Longo D. L.,
Klein H.
Publication year - 1983
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.2920010408
Subject(s) - medicine , hepatosplenomegaly , chronic lymphocytic leukemia , lymphocytosis , apheresis , anemia , leukemia , autoimmune hemolytic anemia , immunology , gastroenterology , platelet , disease
The role of therapeutic reductive lymphapheresis in 59 patients with chronic lymphocytic leukemia (CLL) was reviewed. Reduction in lymphocytosis, lymphadenopathy and hepatosplenomegaly was noted in 50%–60% of the patients studied. In addition to mobilization of the lymphoid tumor load, 40% of the patients showed an improvement in their hemogram. Although apheresis‐induced anemia can occur, reported complications were minimal. These studies suggest that a majority of CLL patients might benefit from therapeutic lymphapheresis.